Advertisement

Topics

Janssen-Cilag AG Release: Three-Year Follow-Up Data Showed Patients Achieved Four-Fold Progression-Free Survival Benefit With Single Agent Imbruvica (Ibrutinib) Vs Temsirolimus At First Relapse In Mantle Cell Lymphoma

20:00 EDT 18 Jun 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Janssen-Cilag AG Release: Three-Year Follow-Up Data Showed Patients Achieved Four-Fold Progression-Free Survival Benefit With Single Agent Imbruvica (Ibrutinib) Vs Temsirolimus At First Relapse In Mantle Cell Lymphoma

NEXT ARTICLE

More From BioPortfolio on "Janssen-Cilag AG Release: Three-Year Follow-Up Data Showed Patients Achieved Four-Fold Progression-Free Survival Benefit With Single Agent Imbruvica (Ibrutinib) Vs Temsirolimus At First Relapse In Mantle Cell Lymphoma"

Advertisement
Quick Search
Advertisement
Advertisement